We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Microbiome Helps Identify Patients with Early-Stage Cancer

By LabMedica International staff writers
Posted on 12 Feb 2019
Nearly 10,000 people are diagnosed with pancreatic cancer in the UK each year, with less than 1% surviving beyond ten years. More...
An early diagnosis can greatly improve the chances of successful treatment, but this poses challenges for this disease as it grows deep inside the body and often shows few symptoms before it has already spread.

Scientists are searching for biological changes that can accurately detect early signs of pancreatic cancer, which could be developed into new screening tests. A current hot topic is the potential role of the microbiome in the development of cancer, with previous studies identifying dramatic disruptions to bacteria in saliva, intestinal and fecal samples collected from pancreatic cancer patients compared to healthy individuals.

Scientists at Zhejiang University (Hangzhou, P.R. China) and their associates recruited a group of 30 patients with early-stage disease (diagnosed with a tumor positioned in the 'head' area of the pancreas) and a similar group of 25 healthy people. Participants were all between 45 and 65 years in age, had no other diseases or oral health problems and had not taken any antibiotics or other drugs for the three months before the study.

The team used sophisticated gene sequencing technologies to examine the microbiome diversity of tongue coat samples, finding that pancreatic cancer patients were colonized by remarkably different tongue coating microbiomes compared to healthy individuals. Microbial DNA was extracted using the Qiagen Mini Kit, was quantified using a Qubit 2.0 Fluorometer, and diluted to 10 ng/μL for PCR amplification in an Eppendorf Mastercycler thermocycler.

The team reported that there was a striking difference of the abundance of four types of bacteria: low levels of Haemophilus and Porphyromonas and high levels of Leptotrichia and Fusobacterium, could distinguish pancreatic cancer patients from healthy individuals. The team hypothesized that the immune system is the most likely link between any confirmed shifts in the microbiome with pancreatic cancer. For example, disease development in the pancreas may influence the immune response in ways that favor the growth of certain bacteria or vice versa.

The authors concluded that complete characterization of the gastrointestinal, saliva and tongue coating microbiomes, and alterations in the microbiotic communities in pancreatic head carcinoma (PHC) patients compared with healthy controls could potentially lead to the development of early diagnostic or preventive tools for PHC. The study was published on January 28, 2019, in the Journal of Oral Microbiology.

Related Links:
Zhejiang University


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.